Pneumologie 2022; 76(S 01): S15
DOI: 10.1055/s-0042-1747721
Abstracts

Early benefits in patient-related-outcomes (PRO) and physical activity (PA) in patients with severe eosinophilic asthma (SEA) treated with benralizumab: interim analysis of the German imPROve Asthma study

M Lommatzsch
1   Universitätsklinikum Rostock; Zentrum für Innere Medizin; Abteilung für Pneumologie
,
S Korn
2   Ikf Pneumologie Mainz; Clinical Research Centre Respiratory Diseases
,
T Grund
3   Astrazeneca Gmbh; Astrazeneca GmbH
,
T Plate
3   Astrazeneca Gmbh; Astrazeneca GmbH
,
H Watz
4   Pneumologisches Forschungsinstitut; an der Lungenclinic Grosshansdorf; Pulmonary Research Institute at Lungenclinic Grosshansdorf
› Author Affiliations
› Further Information
Also available at
 

Objectives Patients (pts) with severe eosinophilic asthma (SEA) often have poor disease control and impaired health-related quality of life. ImPROve Asthma is the first study in Germany to evaluate PROs and PA in pts receiving benralizumab according to EU label in a real-world setting.

Methods This is an interim analysis (data-cut: 28-02-2021) of a prospective study observing patient-reported outcomes (PROs) and physical activity (PA) in uncontrolled SEA patients treated with benralizumab in Germany. For biologic naïve pts who have completed at least 1 month of benralizumab treatment, asthma control (using ACT, ACQ-6) and symptoms (using a visual analogue scale (VAS) from 0 to 10 cm) were analysed. A subgroup (25 pts) using wearable activity trackers were analysed for PA.

Results This analysis included 145 pts (22-90 yrs, median age: 59 yrs, 54.5% women).

After 1 month of treatment, 60.0% of the pts showed a response (increase ≥3 points from baseline (BL)) in the ACT Score. 39.7% of pts were well-controlled after 1 month: 8.3% improved from partly- to well-controlled, 23.3% from poorly- to well-controlled.

In the ACQ-6 a response was observed in 68.7% of pts, with 4.0% improved from partly- to well-controlled, and 12.1% from poorly- to well-controlled).

Symptoms improved compared to baseline VAS (median decrease of 2cm) after 1 month.

The above benefits were appreciable at 7 and 14 days.

The PA increased by a median of 1,335 daily steps after 1 month from BL (7,798 daily steps).

Conclusions Majority of patients with severe eosinophilic asthma experienced substantial early benefit in validated PROs and physical activity after 1 month of benralizumab.

Sponsor of the imPROve asthma study: AstraZeneca

Previously presented at ERS congress 2021



Publication History

Article published online:
11 May 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany